Clinical Trials Browser

Phase 1/2 × Active not recruiting × ibrutinib × Clear all

NCT03960840 2026-06-04

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

Phase 1/2 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02427451 2026-01-27

Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia

Phase 1/2 Active not recruiting

87 enrolled 30 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04446962 2025-09-25

LOC-R01

Phase 1/2 Active not recruiting

Lymphoma, Neurologic Manifestations, Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms

NCT03379428 2024-12-06

Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT03153202 2024-11-19

Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)

Phase 1/2 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell